AKTS
Aktis Oncology, Inc.
$28.42
-0.27 (-0.94%)
At close · Jul 9
Market Cap
$1.55B
Shares
55,277,447
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$28.42
Open$28.70
Day$28.03–29.54
52W$14.72–34.19
Avg vol 30d455K
Short int3.3M · 6.0% float · 5.0d
Short vol79%
DataJan 2026–Jul 2026
Filing10-Q · May 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
+28%
above
RSI (14)
58
neutral
MACD trend
Negative
52-week position
70%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+50%
trailing
6-month return
+37%
trailing
Relative strength
+28%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
3 of 68 funds reported for Jun 30 · net +40.2K sh shares · +3 new
Insider flow
Distributing
Net -$2.8M over 90 days · 100% sells
Short interest
Rising
5.98% of float · ▲ +13.5% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
68 holders — 13F breadth
Squeeze score
59
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
76%
annualized · 1-yr
Max drawdown
−32%
past year
ATR
8.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
+28%
Bullish
RSI (14)
58
Neutral
MACD trend
Negative
Bearish
52-week position
70%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
3 of 68 funds reported for Jun 30 · net +40.2K sh shares · +3 new
Insider flow
Distributing
Net -$2.8M over 90 days · 100% sells
Short interest
Rising
5.98% of float · ▲ +13.5% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
68 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $15
Now $28 · 70%
52-wk high $34
vs 50-day avg +28%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AKTS
this stock
Aktis Oncology, Inc.
|
$1.55B | — | — | — | 6.0% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +9.5% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.63B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +8.2% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AKTS | -8.0% | +49.7% | +36.6% | -11.8% | — |
| SPY | +0.8% | +2.0% | +8.9% | +0.7% | +10.2% |
| vs SPY | -8.8% | +47.8% | +27.7% | -12.5% | — |